Costa Francesco, Jurado-Román Alfonso, Carciotto Gabriele, Becerra-Munoz Victor, Márquez Daniel Tébar, Götzinger Felix, Cerrato Enrico, Misra Shantum, Spissu Marco, Pavani Marco, Mennuni Marco, Chinchilla Fernando Carrasco, Dominguez-Franco Antonio, Muñoz-Garcia Antonio, Navarrete Rocio Sanchez, Varbella Ferdinando, Salinas-Sanguino Pablo, Secemsky Eric A, Mahfoud Felix, Micari Antonio, Alonso-Briales Juan Horacio, Navarro Manuel Jimenez
Área del Corazón, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Hospital Universitario Virgen de la Victoria, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Departamento de Medicina UMA, 29010 Malaga, Spain.
Department of Biomedical and Dental Sciences and of Morphological and Functional Images, University of Messina, 98122 Messina, Italy.
J Clin Med. 2024 Dec 20;13(24):7780. doi: 10.3390/jcm13247780.
Pulmonary embolism (PE) is a life-threatening medical condition caused by the thrombotic occlusion of one or more branches of the lung vasculature, which represents the third most common cause of cardiovascular mortality after myocardial infarction and stroke. PE treatment requires a tailored approach based on accurate risk stratification and personalized treatment decision-making. Anticoagulation is the cornerstone of PE management, yet patients at higher clinical risk may require more rapid reperfusion therapies. In recent years, transcatheter treatment has emerged as a valuable option for patients with intermediate-high or high-risk PE who have contraindications to systemic thrombolysis. Recent advancements in catheter-directed therapies, such as catheter-directed thrombolysis (CDT) and catheter-directed mechanical thrombectomy (CDMT), provide minimally invasive options for swift symptom relief and hemodynamic stabilization. This review aims to provide a practical approach for optimal patient selection and management for PE percutaneous therapies, supported by a thorough evaluation of the current evidence base supporting these procedures. A focus on post-procedural management, the prevention of recurrence, and monitoring for long-term complications such as chronic pulmonary hypertension and post-PE syndrome is also specifically tackled.
肺栓塞(PE)是一种由肺血管系统的一个或多个分支发生血栓性阻塞引起的危及生命的疾病,它是继心肌梗死和中风之后心血管死亡的第三大常见原因。PE治疗需要基于准确的风险分层和个性化治疗决策制定的定制方法。抗凝是PE管理的基石,但临床风险较高的患者可能需要更快速的再灌注治疗。近年来,经导管治疗已成为对全身溶栓有禁忌证的中高风险或高风险PE患者的一种有价值的选择。导管导向治疗的最新进展,如导管导向溶栓(CDT)和导管导向机械血栓切除术(CDMT),为迅速缓解症状和血流动力学稳定提供了微创选择。本综述旨在通过对支持这些手术的当前证据基础进行全面评估来提供一种实用的方法,以实现PE经皮治疗的最佳患者选择和管理。还特别讨论了术后管理、复发预防以及对慢性肺动脉高压和PE后综合征等长期并发症的监测。